José Manuel Bartolomé-Nebreda

Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents

Jerri M. Rook, Zixiu Xiang, Xiaohui Lv et al. · Neuron · 2015 · 128 citations · Full text

Signal Transduction, Molecular Physiology, Mglu 5 +9

O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature

José Manuel Bartolomé-Nebreda, Andrés A. Trabanco, Adriana I. Velter et al. · Expert Opinion on Therapeutic Patents · 2021 · 60 citations

Discovery of VU0409551/JNJ-46778212: An mGlu₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia

Susana Conde-Ceide, Carlos M. Martínez‐Viturro, Jesús Alcázar et al. · ACS Medicinal Chemistry Letters · 2015 · 52 citations · Full text

Psychotropic Medication, Molecular Biology, Psychopharmacology +21

Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia

José Manuel Bartolomé-Nebreda, Francisca Delgado, Maria Luz Martı́n-Martı́n et al. · Journal of Medicinal Chemistry · 2014 · 43 citations · Full text

Psychopharmacology, Pharmacotherapy, Social Sciences +20

Synthesis and Stereochemical Structure−Activity Relationships of 1,3-Dioxoperhydropyrido[1,2-<i>c</i>]pyrimidine Derivatives:  Potent and Selective Cholecystokinin-A Receptor Antagonists

Mercedes Martín‐Martínez, José Manuel Bartolomé-Nebreda, Isabel Gómez‐Monterrey et al. · Journal of Medicinal Chemistry · 1997 · 37 citations · Full text